Tax Reform Takes Its Toll: AbbVie Having Second Thoughts About Shire
This article was originally published in The Pink Sheet Daily
Executive Summary
The $54 billion acquisition could fall through now that AbbVie can’t reap the rewards of a tax inversion, calling into question the value of Shire and its rare disease portfolio.